In his monthly newsletter from the National Institute on Health Policy, former US Senator David Durenberger, who served as a Republican from Minnesota, writes the following:
REPUBLICANS ON THE ATTACK AGAINST HEALTH POLICY CHANGE
Senator Chuck Grassley (R-IA) is mad at Don Berwick for accepting appointment as CMS Administrator without Senate approval. Deprived of his “holds” on Senate action, Grassley is launching media volleys at Berwick. The first is a demand for details of his Institute of Healthcare Improvement (IHI) compensation and a list of potentially conflicted IHI sponsors/contributors. The second, a demand with his Finance Committee successor Orrin Hatch (R-UT), that Berwick “request an appearance in front of the Finance Committee during September or “appear in front of a panel of interested Senators if a hearing is not scheduled.”
Princeton health economist Uwe Reinhardt, whose accented German heritage makes his comments on health policy makers funnier than Stewart and Colbert, turned deadly serious in defending Berwick. “Don Berwick has done more than anyone I know to make the lives of Americans safer and better. The smears against him (by Republican Senators) are obscene.”
Uwe is right. President Obama resubmitted Berwick’s nomination last week. That may mean he, and Berwick, have decided to take these guys on. Recalling how Hillary Clinton took on a Room 207 in the Capitol full of members of the Senate in early 1994, and won hands down, I have been eager for Berwick to do the same asap.
Opinions on other issues in news, journals, PR, advertising, marketing
Like Michael Corleone of science reporting that @garyschwitzer is (he tries to get out, bullshit disguised as #science #journalism keeps pulling him back in!), he drops this on @nytimes idiocy 🙄 in reporting T1 diabetes "cure"
HT @HealthNewsRevu
https://www.healthnewsreview.org/2021/11/cure-for-type-1-diabetes-weve-been-down-this-road-before-with-ny-times/
A great read on this weekend’s NYT claims of a cure for Type 1.
Cure for Type 1 diabetes? We’ve been down this road before with NY Times https://www.healthnewsreview.org/2021/11/cure-for-type-1-diabetes-weve-been-down-this-road-before-with-ny-times/
"But it is the framing and the emphasis of the #journalism by a leading science journalist at a leading newspaper that demands scrutiny. It has an impact on readers and on sick people that may cause harm by promoting false hope about extremely preliminary research"
👍👏💪 truth https://twitter.com/garyschwitzer/status/1465399358137024518
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Paul Scott
October 1, 2010 at 11:26 amGrassley seems to have done so much for COI without understanding in any way who the bad guys are. I would think the donations to Berwick’s employer would be a snooze — by all means, they should cough them up — especially compared to the millions that are likely to have been earned by Orin Hatch’s son Scott, a lobbyist for Pfizer. Dad, of course, wrote the drug patent law.
http://www.sourcewatch.org/index.php?title=Pfizer_Inc
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like